Dr. Stephen Munk has been with Ash Stevens Inc. since 1997, serving as President
since 1998 and CEO since 2001. He is experienced in drug discovery, development, and
manufacturing both as a scientist and as a manager. Prior to joining Ash Stevens, Dr.
Munk worked at Allergan, Inc. as a drug discovery scientist
and subsequently as the
co-team leader of the adrenergic drug discovery team. Under Dr. Munk’s stewardship,
Ash Stevens has received ten regulatory approvals for the manufacture of novel
drug substances to treat serious life-threatening conditions. These approvals include
bortezomib, clofarabine, 5-azacitidine, amotosalen, and ponatinib.
Read More